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Patrick M. Honore* and Herbert D. SpapenSee related research by Hansen et al., http://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1210-zNecrotizing soft tissue infection (NSTI) is a devastating
condition with high morbidity and a dismal prognosis.
Timely and adequate surgery and early aggressive treat-
ment of associated sepsis are imperative to improve
survival [1–3]. Pentraxin-3 (PTX3) is a glycoprotein
released by endothelial and inflammatory cells upon
stimulation by cytokines and endotoxins. In contrast with
C-reactive protein (CRP) which is produced in the liver in
response to systemic inflammation, PTX3 is thought to
better reflect local vascular inflammation and bacterial
load [2]. PTX3 assessment might thus be a more appropri-
ate marker of severity and prognosis of NSTI. This was
corroborated by Hansen et al. [1], who reported a signifi-
cant association between high baseline PTX3 levels and
occurrence of septic shock, amputation, dialysis need, and
risk of death in a large cohort of patients with NSTI.
PTX3 also performed better than the “classical” inflamma-
tory markers CRP and procalcitonin (PCT).
These findings are interesting but mandate careful re-
flection. First, they are not unexpected. Measurement of
PTX3 has been shown to improve patient risk* Correspondence: Patrick.Honore@az.vub.ac.be
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ing sepsis may contribute to tissue damage and predict
poor patient outcome [2]. Second, when looking closely
at the study results, PTX3 levels appeared to be fairly in
line with PCT concentrations for assessing NSTI-
associated morbidity and mortality. PCT also outper-
forms CRP in predicting severity of infection and organ
dysfunction in sepsis [4] but is more readily available
than PTX3. Finally, many patients with NSTI develop
acute kidney injury, necessitating renal replacement
therapy (RRT) (25 % of the patients studied by Hansen
et al.!). PTX3 has a molecular weight of approximately
35 kDa [2] and thus in theory can be removed by RRT.
Recently, Schilder et al. [5] demonstrated some adsorp-
tion but no elimination of PTX3 by convection across
the system of continuous veno-venous hemofiltration
(CVVH), resulting in unaltered plasma levels. Whether
this is also relevant when CVVH is performed at higher
convection flux or with different types of dialysis mem-
branes (especially highly adsorptive) remains to be
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cause massive necrosis, as in the case of NSTI. Since
NSTI is an uncommon disease, treatment and surveil-
lance procedures in the ICU rely, primarily, on know-
ledge obtained from studies on septic patients. Thus, it
is important to establish solid evidence for the treatment
strategies in patients with NSTI as well, which also
includes investigating the different aspects of the im-
munological response. In addition, suspicion of NSTI is
currently based on the patient’s clinical presentation,is article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Honore and Spapen Critical Care  (2016) 20:173 Page 2 of 2making it interesting to investigate the predicting abilities
of new biomarkers, such as PTX3.
Second, they underline that both PTX3 and PCT are
good predictors of morbidity and mortality. We agree
with this and the fact that both biomarkers outperform
CRP. Our results suggest that PTX3 can be considered a
reliable marker of infections on equal terms to PCT in
patients with NSTI. However, the PTX3 level was signifi-
cantly higher in patients needing amputation. This was
not the case for CRP or PCT. PTX3 might therefore
be useful to identify different subgroups of patients
from PCT.
Third, Honore and Spapen speculate whether PTX3
can be removed by RRT, thus altering the levels in
the study cohort. Despite PTX3 having a molecular
weight of 45 kDa as a monomer, it forms an octamer
in plasma composed of two covalently linked tetra-
mers with a weight above 400 kDa [6–8]. It is there-
fore unlikely that PTX3 will be removed by RRT.
Moreover, the baseline samples were taken upon admis-
sion and before initiation of RRT in the vast majority
of patients.
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